Skip to main content
Erschienen in: Journal of Neurology 3/2009

01.08.2009

Management of non-motor complications in Parkinson’s disease

verfasst von: Ken-ichi Fujimoto

Erschienen in: Journal of Neurology | Sonderheft 3/2009

Einloggen, um Zugang zu erhalten

Abstract

This paper summarizes the methods we devised for the treatment of psychosis, orthostatic hypotension, and mood disorders among the various non-motor complications of Parkinson’s disease. Psychosis may not manifest when a patient believes in his/her delusions. If left untreated over a prolonged period, however, the delusions progress to paranoia that is very difficult to cure. Accordingly, enquiries should be made during routine examinations to detect the presence of psychosis and facilitate early discovery. Atypical antipsychotics are used when psychosis does not improve after reducing the doses of antiparkinson drugs. We achieved favorable results by using mianserin hydrochloride prior to this step, with efficacy being observed for hallucinations and mild delusions that often manifested at night. This drug does not act as a dopamine receptor blocker, so it has the advantage of not aggravating motor symptoms. With this therapy, it is also possible to improve motor symptoms without inducing psychosis by reducing the doses of antiparkinson drugs and locally stimulating the motor loop by deep brain stimulation of the subthalamic nucleus. We previously introduced leg-holding exercises for the treatment of orthostatic hypotension, through which blood pooled in the veins is returned to the systemic circulation by holding the knees. This can be done easily and is free of adverse reactions. Mood disorders are difficult to cope with in patients with Parkinson’s disease, but may be treated by selecting an appropriate dopamine agonist while giving consideration to affinity for the dopamine D3 receptor. However, treatment becomes complicated when the dopamine receptor is overstimulated. Here we report on cases of successfully treated pathological gambling and dopamine dysregulation syndrome, which are considered difficult to manage. The solution may differ depending on a patient’s environment, and it is not easy to prescribe therapy based on evidence-based medicine. The best therapy should be selected by maintaining communication with the patient and developing a relationship built on trust.
Literatur
1.
Zurück zum Zitat Ad Hoc Committee on the Guidelines for the Treatment of Parkinson’s Disease. Japanese Neurological Society (2002) Guidelines for the treatment of Parkinson’s disease. Clin Neurol 42:430–494 Ad Hoc Committee on the Guidelines for the Treatment of Parkinson’s Disease. Japanese Neurological Society (2002) Guidelines for the treatment of Parkinson’s disease. Clin Neurol 42:430–494
2.
Zurück zum Zitat Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, Zappia M, Musch B, The Depression/Parkinson Italian Study Group (2006) Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol 253:601–607PubMedCrossRef Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, Zappia M, Musch B, The Depression/Parkinson Italian Study Group (2006) Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol 253:601–607PubMedCrossRef
3.
Zurück zum Zitat Brogden RN, Heel RC, Speight TM, Avery GS (1978) Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 16:273–301PubMedCrossRef Brogden RN, Heel RC, Speight TM, Avery GS (1978) Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 16:273–301PubMedCrossRef
4.
Zurück zum Zitat Coldwell MC, Boyfield I, Brown T, Hagan JJ, Middlemiss DN (1999) Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2 (long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 127:1696–1702PubMedCrossRef Coldwell MC, Boyfield I, Brown T, Hagan JJ, Middlemiss DN (1999) Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2 (long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 127:1696–1702PubMedCrossRef
5.
Zurück zum Zitat Doi N, Sameshima T, Suwa H, Mera H, Nagao T, Yokochi M, Nakamura M, Isse K (2007) Electroconvulsive therapy for neurological disorders. Brain Nerve 59:313–320PubMed Doi N, Sameshima T, Suwa H, Mera H, Nagao T, Yokochi M, Nakamura M, Isse K (2007) Electroconvulsive therapy for neurological disorders. Brain Nerve 59:313–320PubMed
6.
Zurück zum Zitat Evans AH, Katzenschlager R, Paviour D, O’Sullivan JD, Appel S, Lawrence AD, Lee AJ (2004) Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19:397–405PubMedCrossRef Evans AH, Katzenschlager R, Paviour D, O’Sullivan JD, Appel S, Lawrence AD, Lee AJ (2004) Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19:397–405PubMedCrossRef
7.
Zurück zum Zitat Fenelon G, Mahieux F, Huon R, Ziegler M (2000) Hallucinations in Parkinson’s disease. Prevalence, phenomenology and risk factors. Brain 123:733–745PubMedCrossRef Fenelon G, Mahieux F, Huon R, Ziegler M (2000) Hallucinations in Parkinson’s disease. Prevalence, phenomenology and risk factors. Brain 123:733–745PubMedCrossRef
8.
Zurück zum Zitat Ferrara JM, Stacy M (2008) Impulse–control disorders in Parkinson’s disease. CNS Spectra 13:690–698 Ferrara JM, Stacy M (2008) Impulse–control disorders in Parkinson’s disease. CNS Spectra 13:690–698
9.
Zurück zum Zitat Frieling H, Hillemacher T, Ziegenbein M, Neundörfer B, Bleich S (2007) Treating dopamimetic psychosis in Parkinson’s disease: structured review and meta-analysis. Eur Neuropsychopharmacol 17:165–171PubMedCrossRef Frieling H, Hillemacher T, Ziegenbein M, Neundörfer B, Bleich S (2007) Treating dopamimetic psychosis in Parkinson’s disease: structured review and meta-analysis. Eur Neuropsychopharmacol 17:165–171PubMedCrossRef
10.
Zurück zum Zitat Fujimoto K (2004) Patient selection in stereotaxic neurosurgery for Parkinson’s disease: a guide to stereotactic brain operations. Neurol Surg 32:1067–1075 Fujimoto K (2004) Patient selection in stereotaxic neurosurgery for Parkinson’s disease: a guide to stereotactic brain operations. Neurol Surg 32:1067–1075
11.
Zurück zum Zitat Fujimoto K (2008) Pathological gambling and Parkinson disease. Brain Nerve 60:1039–1046PubMed Fujimoto K (2008) Pathological gambling and Parkinson disease. Brain Nerve 60:1039–1046PubMed
12.
Zurück zum Zitat Fujimoto K, Sayama S, Shizuma N, Ikeguchi K, Nakano I (2000) Mianserin therapy for psychosis in parkinsonism. Neurol Med 53:274–281 Fujimoto K, Sayama S, Shizuma N, Ikeguchi K, Nakano I (2000) Mianserin therapy for psychosis in parkinsonism. Neurol Med 53:274–281
13.
Zurück zum Zitat Giovannoni G, O’Sullivan JD, Turner K, Manson AJ, Lees AJL (2000) Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiat 68:423–428PubMedCrossRef Giovannoni G, O’Sullivan JD, Turner K, Manson AJ, Lees AJL (2000) Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiat 68:423–428PubMedCrossRef
14.
Zurück zum Zitat Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 43:2227–2229PubMed Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 43:2227–2229PubMed
15.
Zurück zum Zitat Goldstein DS (2003) Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol 2:669–676PubMedCrossRef Goldstein DS (2003) Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol 2:669–676PubMedCrossRef
16.
Zurück zum Zitat Ikeguchi K, Kuroda A (1995) Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatry Clin Neurosci 244:320–324PubMedCrossRef Ikeguchi K, Kuroda A (1995) Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatry Clin Neurosci 244:320–324PubMedCrossRef
17.
18.
Zurück zum Zitat Lemke MR, Brecht HM, Koester J, Reichmann H (2006) Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s disease. J Neurol Sci 248:266–270PubMedCrossRef Lemke MR, Brecht HM, Koester J, Reichmann H (2006) Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s disease. J Neurol Sci 248:266–270PubMedCrossRef
19.
Zurück zum Zitat Mathias CJ (2005) Cardiovascular autonomic dysfunction in Parkinson’s disease and parkinsonian syndromes. In: Ebadi M, Pfeiffer RF (eds) Parkinson’s disease. CRC Press LLC, New York, pp 295–317 Mathias CJ (2005) Cardiovascular autonomic dysfunction in Parkinson’s disease and parkinsonian syndromes. In: Ebadi M, Pfeiffer RF (eds) Parkinson’s disease. CRC Press LLC, New York, pp 295–317
20.
Zurück zum Zitat Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G (2005) Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord 20:958–963PubMedCrossRef Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G (2005) Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord 20:958–963PubMedCrossRef
21.
Zurück zum Zitat Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C (2007) Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 22:313–318PubMedCrossRef Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C (2007) Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 22:313–318PubMedCrossRef
22.
Zurück zum Zitat Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, Aarsland D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, Stacy M, Gwinn-Hardy K, Voon V, Goetz C (2007) Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord 22:1061–1068PubMedCrossRef Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, Aarsland D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, Stacy M, Gwinn-Hardy K, Voon V, Goetz C (2007) Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord 22:1061–1068PubMedCrossRef
23.
Zurück zum Zitat Task force on ECT (2001) The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging, 2nd edn. American Psychiatric Association, Washington Task force on ECT (2001) The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging, 2nd edn. American Psychiatric Association, Washington
24.
Zurück zum Zitat Voon V, Moro E, Saint-Cyr JA, Lozano AM, Lang AE (2005) Psychiatric symptoms following surgery for Parkinson’s disease with an emphasis on subthalamic stimulation. Adv Neurol 96:130–147PubMed Voon V, Moro E, Saint-Cyr JA, Lozano AM, Lang AE (2005) Psychiatric symptoms following surgery for Parkinson’s disease with an emphasis on subthalamic stimulation. Adv Neurol 96:130–147PubMed
25.
Zurück zum Zitat Weintraub D, Hurtig HI (2007) Presentation and management of psychosis in Parkinson’s disease and dementia with Lewy bodies. Am J Psychiatry 164:1491–1498PubMedCrossRef Weintraub D, Hurtig HI (2007) Presentation and management of psychosis in Parkinson’s disease and dementia with Lewy bodies. Am J Psychiatry 164:1491–1498PubMedCrossRef
26.
Zurück zum Zitat Wolters ECh (2001) Intrinsic and extrinsic psychosis in Parkinson’s disease. J Neurol 248(suppl 3):III/22–III/27 Wolters ECh (2001) Intrinsic and extrinsic psychosis in Parkinson’s disease. J Neurol 248(suppl 3):III/22–III/27
Metadaten
Titel
Management of non-motor complications in Parkinson’s disease
verfasst von
Ken-ichi Fujimoto
Publikationsdatum
01.08.2009
Verlag
D. Steinkopff-Verlag
Erschienen in
Journal of Neurology / Ausgabe Sonderheft 3/2009
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-009-5245-9

Weitere Artikel der Sonderheft 3/2009

Journal of Neurology 3/2009 Zur Ausgabe

Events

Foreword

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.